At 0.1x sales, 0.9x book, and a 6.4 forward P/E, the market is clearly pricing ADNT as a distressed cyclical rather than a stable compounder. The 0.7 forward PEG superficially signals growth-adjusted value, but that is undermined by a projected EPS collapse to -$3.67 next year and an operating margin of -17.50%, which screams earnings volatility. An Altman Z-Score of 1.8 places the company in financial distress territory, and with ROIC at -2.30%, capital is currently being destroyed, not compounded. This is not a quality franchise temporarily mispriced; it is a balance-sheet-constrained cyclical trading at a discount because the market doubts durability.